Your English writing platform
Discover LudwigSuggestions(1)
Exact(2)
Typically, this clinical profile includes macrocytic anemia, a normal to increased platelet count, mild leukopenia, hypolobulated megakaryocytes in the bone marrow, a medullary blast count <5%, and an isolated del 5q) abnormality including a common deleted region between 5q31 and 5q33 [ 4, 7].
The 5q− syndrome is recognised as a distinct clinical entity according to the World Health Organization classification and is defined by a medullary blast count of <5% and the presence of the del 5q) as the sole karyotypic abnormality (Vardiman et al, 2002).
Similar(58)
This is an important limitation, as patients with a complex karyotype and del 5q) are eligible for treatment only if they have no more than one cytopenia (i.e., anemia, neutropenia, or thrombocytopenia) and their medullary bone marrow blast count is <5%.
The blast count in bone marrow of the patients in AML CR phase was ≤5%, the blast count in bone marrow with the patient in AML PR phase was between >5% and ≤20%.
The definition of CR or PR is based on blast count after the completion of standard chemotherapy.
The AML samples contained 80 100% blast cells after thawing, regardless of the blast count at diagnosis.
The blast count was below 20% in each animal.
Twentypercentt achieved a reduction in marrow blast count, with less than 5% blasts at morphologic exam.
Randomization was not stratified according to baseline bone marrow blast count, but counts were balanced between treatment arms: most patients (72%) had a blast count >30%, while 43% had a blast count >50%.
Responders had a median BM blast count of 44% (range = 29 65%) at baseline, compared with a median BM blast count of 57% (range = 33 92%) in nonresponders (Table 3).
Four patients had an elevated blast count before treatment; three of these were evaluated after treatment, in which all three patients normalized their blast count.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com